

Received Date : 06-Apr-2016

Revised Date : 25-Jul-2016

Accepted Date : 26-Jul-2016

Article type : Reviews

Editor : Alessio Aghemo

Ribavirin revisited in the era of direct-acting antiviral therapy for hepatitis C virus infection

Jordan J. Feld,^{*} Ira M. Jacobson,[†] Mark S. Sulkowski,[§] Fred Poordad,^{||} Fernando Tatsch,[¶] Jean-Michel Pawlotsky^{**,#†}

^{}Toronto Centre for Liver Disease, Toronto General Hospital, Toronto, Canada;*

[†]Mount Sinai Beth Israel, New York, USA; [§]Johns Hopkins University, Baltimore, MD, USA;

*^{||}Texas Liver Institute, University of Texas Health Science Center, San Antonio, Texas, USA; [¶]AbbVie Inc., North Chicago, Illinois, USA; ^{**}National Reference Center for Viral Hepatitis B, C and Delta, Department of Virology, Hôpital Henri Mondor, Université Paris-Est, Créteil, France; and ^{#†}INSERM U955, Créteil, France*

Corresponding author:

Name: Jordan J. Feld

Address: Toronto Centre for Liver Disease, Toronto General Hospital, 200 Elizabeth Street, 9EN-240, Toronto, Ontario, M5G 2C4

Telephone: +1 (416) 340 4584

Fax: +1 (416) 340 4533

Email: jordan.feld@uhn.ca

This article has been accepted for publication and undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process, which may lead to differences between this version and the Version of Record. Please cite this article as doi: 10.1111/liv.13212

This article is protected by copyright. All rights reserved.

Abbreviations: HCV, hepatitis C virus; peginterferon, pegylated interferon; SVR, sustained virologic response; RAS, resistance-associated substitution; AE, adverse event; DAA, direct-acting antiviral; GT, genotype; EASL, European Association for the Study of the Liver; AASLD, American Association for the Study of Liver Diseases; IDSA, Infectious Diseases Society of America; RNA, ribonucleic acid; FDA, U.S Food and Drug Administration; HIV, human immunodeficiency virus; PRO, patient-reported outcome.

Conflicts of interest:

AbbVie funded the study and participated in the writing, review, and approval of the content of this manuscript.

JJ Feld: Grant/Research Support: AbbVie, Boehringer Ingelheim, Gilead, Janssen, Merck; Scientific Consulting/Advisory Board: AbbVie, BMS, Gilead, Janssen, Merck, Theravance.

IM Jacobson: Research support: AbbVie, BMS, Gilead, Janssen, Merck; Consultant/Advisor: AbbVie, BMS, Gilead, Intercept, Janssen, Merck; Trek Speaker: AbbVie, Gilead, Intercept, Janssen, Merck.

F Poordad: Grant/Research Support: AbbVie, Achillion Pharmaceuticals, Anadys Pharmaceuticals, Biolex Therapeutics, Boehringer Ingelheim, BMS, Genentech, Gilead, GlaxoSmithKline, GlobelImmune, Idenix Pharmaceuticals, Idera Pharmaceuticals, Intercept Pharmaceuticals, Janssen, Medarex, Medtronic, Merck, Novartis, Santaris Pharmaceuticals, Scynexis Pharmaceuticals, Vertex Pharmaceuticals, ZymoGenetics; Speaker: Gilead, Kadmon, Merck, Onyx/Bayer, Genentech, GlaxoSmithKline, Salix, Vertex; Consultant/Advisor: AbbVie, Achillion Pharmaceuticals, Anadys Pharmaceuticals, Biolex Therapeutics, Boehringer Ingelheim, BMS, Gilead, GlaxoSmithKline, GlobelImmune, Idenix, Merck, Novartis, Tibotec/Janssen, Theravance, Vertex.

MS Sulkowski: Grant/Research Support (paid to Johns Hopkins University): AbbVie, BMS, Gilead, Janssen, Merck; Consultant/Advisor: AbbVie, Achillion, BMS, Gilead, Janssen, Merck.

F Tatsch: AbbVie employee and may hold AbbVie stock or options.

JM Pawlotsky: Advisor: AbbVie, Achillion, BMS, Gilead, Janssen, Merck, Novartis; Research Grants; Gilead.

Author's contributions:

JJ Feld: Analysis and interpretation of data; drafting of the manuscript; critical revision of the manuscript for important intellectual content.

IM Jacobson: Analysis and interpretation of data; critical revision of the manuscript for important intellectual content.

F Poordad: Analysis and interpretation of data; critical revision of the manuscript for important intellectual content.

MS Sulkowski: Analysis and interpretation of data; critical revision of the manuscript for important intellectual content.

F Tatsch: Analysis and interpretation of data; critical revision of the manuscript for important intellectual content.

JM Pawlotsky: Analysis and interpretation of data; critical revision of the manuscript for important intellectual content.

Writing Assistance: Medical writing support was provided by Sian Deeves of Medical Expressions, funded by AbbVie.

Key points:

- Ribavirin has been an integral component of treatment for hepatitis C virus (HCV) infection for the past two decades
- In the interferon-free era of HCV treatment, ribavirin has retained an important role in the optimal treatment of some difficult-to-cure subgroups of patients
- The safety profile of ribavirin is improved when co-administered with all-oral direct-acting antiviral (DAA) combinations in the absence of interferon
- Recently, new insights have been gained into the antiviral mechanism by which ribavirin delays or prevents the emergence of resistance-associated substitutions (RASs)

Abstract

Over the past two decades, ribavirin has been an integral component of treatment for HCV infection, where it has been shown to improve the efficacy of (pegylated) interferon. However, due to treatment-limiting side effects and its additive toxicity with interferon, the search for interferon- and ribavirin-free regimens has been underway. The recent approvals of all-oral direct acting antivirals (DAAs) have revolutionized the HCV therapeutic landscape, and initially it was expected that the role of ribavirin with DAA regimens would be eliminated. On the contrary, what we have witnessed is that ribavirin retains an important role in the optimal treatment of some subgroups of patients, particularly those that historically have been considered the most difficult to cure. Fortunately, it has also been recognized that the safety profile of ribavirin is improved when co-administered with all-oral DAA combinations in the absence of interferon. Despite the antiviral mechanism of action of ribavirin being poorly understood, we now have a range of novel insights into the potential role of ribavirin in all-oral DAA HCV treatment, and greater insight into the antiviral mechanism by which it continues to provide clinical benefit for defined patient groups.

Key words

Hepatitis C virus, ribavirin, direct-acting antiviral, interferon-free

Abstract word count (including key words): 199

Introduction: the role of ribavirin in the era of interferon

The guanosine analogue ribavirin has been an important component of interferon-based regimens for hepatitis C virus (HCV) infection since the 1990s, when it was shown that adding it to conventional interferon significantly increased treatment efficacy by decreasing the risk of post-treatment viral relapse (1). Similarly, the combination of ribavirin and pegylated interferon (peginterferon) was shown to be superior to peginterferon alone (Table 1) (2), due to higher on-treatment responses and, more importantly, lower rates of relapse following therapy.

The introduction of the first-generation HCV protease inhibitors boceprevir and telaprevir to peginterferon/ribavirin regimens boosted sustained virologic response (SVR) rates even further (3-7). With these new potent agents, it was hoped that ribavirin would no longer be necessary; however, eliminating ribavirin from the regimen altogether significantly reduced response rates and increased rates of breakthrough with virus resistance-associated substitutions (RASs). Ribavirin dosage

reduction was shown to be safe and did not negatively impact SVR rates unless dosage was reduced by more than 50% of the recommended ribavirin dosage (8).

Despite improving the efficacy of interferon-based therapy, ribavirin is associated with a number of treatment-limiting adverse events (AEs), particularly hemolytic anemia (9-11). Other ribavirin-related AEs include pruritus, rash, insomnia, mild abdominal discomfort, and upper respiratory tract symptoms (9-11). Furthermore, the combination with interferon or peginterferon results in higher rates of some AEs, compared with either agent alone (Fig. 1A, 1B) (1,2). Finally, due to a teratogenic effect in animals (12), ribavirin is contraindicated during pregnancy, warranting a Category X designation, and contraception is required in all women of child-bearing potential, including those with male partners taking the medication (13,14).

Ribavirin is not metabolized via a cytochrome P450-mediated mechanism and, therefore, has a low potential for drug–drug interactions (13). However, there are issues with a small number of agents with additive toxicity, e.g. the nucleoside reverse transcriptase inhibitors zidovudine and didanosine as well as the immunosuppressant drug azathioprine. No issues have been identified with ribavirin and any approved direct-acting antiviral (DAA) therapies for HCV.

The role of ribavirin in the interferon-free era

In the interferon-free era of HCV treatment, most clinical trials have been designed to systematically evaluate DAA regimens with or without ribavirin. Ribavirin's role was expected to diminish or even be eliminated over time, but pivotal trial data indicate that, for certain regimens, it remains an important component for the optimal treatment of some patients. Deciding whether to include ribavirin as a therapy component, and how best to manage its use, largely depends on HCV genotype (GT), GT subtype, fibrosis stage, and the treatment regimen itself (Table 1).

Optimizing therapy by maximizing SVR rates in HCV GT1-infected patients

Clinical trial data for interferon-free DAA combinations have shown that adding ribavirin results in higher SVR rates in select GT1-infected patients. However, it should be recognized that, even without ribavirin, highly potent DAA combinations that target multiple components of the HCV lifecycle have a high barrier to resistance and achieve nearly universal on-treatment rates of undetectable HCV RNA. Therefore, in most cases, adding ribavirin maximizes SVR rates by reducing post-treatment viral relapse, presumably through action within hepatocytes.

Sofosbuvir, a nucleotide analogue NS5B inhibitor, has been evaluated in combination with the NS5A inhibitor ledipasvir with and without ribavirin in patients with GT1 infection in the phase 3 trials ION-1, ION-2, and ION-3 (15-17). Among treatment-naive patients recruited in ION-1 (N=865) and ION-3 (N=647), SVR rates in all treatment arms were high and adding ribavirin did not appear to confer additional benefit over that observed with ledipasvir/sofosbuvir (15,17). However, among treatment-experienced patients recruited in ION-2 (N=440), the addition of ribavirin was shown to increase SVR rates compared with ledipasvir/sofosbuvir in certain patient subsets (16). For example, 4/87 (4.6%) patients without cirrhosis treated for 12 weeks with ledipasvir/sofosbuvir and no ribavirin experienced post-treatment viral relapse, compared with 0/89 of their counterparts treated with ribavirin. Furthermore, the relatively few patients infected with the HCV GT1b subtype, with or without cirrhosis, tended to achieve a numerically lower SVR rate when treated for 12 weeks without ribavirin (20/23 [87.0%]), compared with those treated for 12 weeks with ribavirin (23/23 [100%]) (16). However, it is difficult to draw conclusions from study samples that were not powered to detect differences within subpopulations, and may explain why the approval for 12-week treatment with ledipasvir/sofosbuvir in treatment-experienced patients without cirrhosis does not include the use of ribavirin for either GT1 subtype (18,19). In ION-2, the lack of benefit with ribavirin seemed clear. In GT1-infected treatment-experienced cirrhotic patients, treatment with ledipasvir/sofosbuvir with or without ribavirin for 24 weeks achieved SVR rates of 100% (n=22 in each), while treatment for 12 weeks with or without ribavirin achieved SVR rates of 82% and 86%, respectively (n=22 in each) (16). This led to what seemed like the incontrovertible recommendation that 24-week ledipasvir/sofosbuvir treatment in patients with compensated cirrhosis be administered without ribavirin (18,19). However, in the SIRIUS study (N=155) of GT1-infected patients with cirrhosis who had failed therapy with peginterferon/ribavirin and a protease inhibitor, treatment with ledipasvir/sofosbuvir with ribavirin for 12 weeks achieved a similar SVR rate to treatment with ledipasvir/sofosbuvir alone for 24 weeks (96% and 97%, respectively) (20). This again highlights the need to ensure studies are adequately powered to evaluate important sub-groups. Inclusion of only 22 treatment-experienced patients with cirrhosis in each arm of ION-2 led to the incorrect conclusion that ribavirin was of no benefit.

A pooled analysis of phase 2 and 3 studies, including the SIRIUS study, provided additional evidence that ribavirin may enhance SVR rates in a 12-week ledipasvir/sofosbuvir regimen in the subset of treatment-experienced HCV GT1-infected patients with compensated cirrhosis (21). With 12 weeks of treatment, SVR rates were numerically higher with ribavirin than without (95.6% [152/159] versus 90.1% [64/71]), whereas there was no evidence of a ribavirin-related efficacy boost in those treated for 24 weeks (21). Subsequently, prescribing information has been

updated to include an alternative recommendation of 12 weeks ledipasvir/sofosbuvir with ribavirin for patients with compensated cirrhosis who have failed a prior course of therapy (18,19). Among patients with compensated cirrhosis, European Association for the Study of the Liver (EASL) guidelines recommend treatment with ledipasvir/sofosbuvir with ribavirin for 12 weeks in both treatment-naive and treatment-experienced patients (22), whereas American Association for the Study of Liver Diseases (AASLD) guidelines recommend ledipasvir/sofosbuvir for 12 weeks without ribavirin in treatment-naive patients and ledipasvir/sofosbuvir for 12 weeks with ribavirin or 24 weeks without ribavirin in treatment-experienced patients (23).

Similar observations have recently been made in real-world clinical practice. Results from a sub-analysis of the TRIO Network that evaluated the efficacy of ledipasvir/sofosbuvir with or without ribavirin in treatment-experienced cirrhotic patients, albeit with low patient numbers, showed numerically higher SVR rates in those receiving ledipasvir/sofosbuvir with ribavirin for 12 weeks (96%, 25/26) compared with those receiving ledipasvir/sofosbuvir without ribavirin for 12 (84%, 102/121) or 24 weeks (92%, 303/329) (24).

Closer inspection of pooled ledipasvir/sofosbuvir data suggests that the benefit of ribavirin seems to be greatest in those with RASs detectable at baseline. In a pooled analysis of GT1-infected treatment-naive and treatment-experienced patients with compensated cirrhosis and detectable NS5A RASs at baseline, the addition of ribavirin resulted in numerically higher SVR rates (12 weeks: 88% [without ribavirin] versus 94% [with ribavirin]; 24 weeks: 85% versus 100%), by reducing rates of relapse (25). The impact on the rate of SVR12 was predominantly observed in HCV GT1a-infected treatment-experienced cirrhotic patients with baseline NS5A RASs that conferred >100-fold shift in EC₅₀. Conversely, in patients without detectable NS5A RASs at baseline, SVR rates were unaffected by treatment extension or addition of ribavirin (25). These data suggest that ribavirin may improve DAA efficacy in patients infected with a detectable proportion of resistant HCV, but the mechanism of this effect remains poorly understood.

The possible benefit of ribavirin addition in patients with GT1a infection has also been demonstrated in those receiving the approved combination of ombitasvir (an NS5A inhibitor), paritaprevir (an NS3/4A protease inhibitor, pharmacokinetically enhanced by ritonavir co-administration), and dasabuvir (a non-nucleoside NS5B inhibitor). In the randomized, placebo-controlled SAPPHERE trials, overall SVR rates of 96% were demonstrated in GT1a treatment-naive and -experienced patients without cirrhosis who received 12 weeks of ombitasvir/paritaprevir/ritonavir plus dasabuvir and ribavirin (26-29). Subsequently, a set of randomized, regimen-controlled trials examined the efficacy and safety of this 12-week regimen with and without ribavirin in treatment-naive patients without cirrhosis, infected with either HCV GT1a (PEARL-IV) (30) or HCV GT1b (PEARL-III) (30), or treatment-experienced,

GT1b-infected patients (PEARL-II) (31). These trials showed that ribavirin confers a possible benefit in treatment-naïve, GT1a-infected patients without cirrhosis, in whom it numerically increased SVR rates from 90% to 97% (30). In contrast, in GT1b-infected patients without cirrhosis, 100% (300/300) SVR rates were achieved without ribavirin, even among those with a null response to prior peginterferon plus ribavirin therapy (28-31). In the TURQUOISE-II study (N=380), which enrolled HCV GT1-infected, treatment-naïve and -experienced patients with cirrhosis, SVR12 rates were high in both GT1b- (99.2% [118/119]) and GT1a-infected (91.6% [239/261]) individuals treated with ombitasvir/paritaprevir/ritonavir plus dasabuvir and ribavirin for 12 or 24 weeks (28,29,32). The longer therapy duration improved the SVR rate in GT1a-infected patients with a prior null response to peginterferon plus ribavirin, but conferred no additional benefit in the rest of the patient population. The high response in HCV GT1b patients with ribavirin led to the TURQUOISE-III study, a single-arm (N=60) trial, to evaluate whether HCV GT1b-infected patients with cirrhosis could be effectively treated with the 12-week ribavirin-free ombitasvir/paritaprevir/ritonavir plus dasabuvir regimen. All 60 patients achieved SVR12; however, due to the small number of patients enrolled into the study, 95% confidence intervals were 94–100% (33). Collectively, these data for ombitasvir/paritaprevir/ritonavir plus dasabuvir show that adding ribavirin is useful for HCV GT1a but does not confer additional benefit in HCV GT1b-infected patients, even those with compensated cirrhosis.

These examples demonstrate that, with multiple DAA regimens, ribavirin may maximize SVR rates through reducing relapse rates in select HCV GT1-infected patients, particularly those with GT1a, in which a lower barrier to resistance has been demonstrated with the protease, NS5A, and non-nucleotide polymerase inhibitor classes compared. In combination with GT1b agents with a higher barrier to resistance, particularly nucleotide polymerase inhibitors, the ribavirin effect is less clear.

However, small studies may be misleading. Ribavirin did not appear to affect the SVR12 rates in the COSMOS trial (N=167), which randomized HCV GT1-infected, treatment-naïve or -experienced patients to receive sofosbuvir and the NS3/4A protease inhibitor simeprevir, with and without ribavirin, for 12 or 24 weeks (34). The high SVR rates in all groups suggested that ribavirin was of no benefit and that the Q80K substitution, which affects the response of HCV GT1a-infected patients to simeprevir, did not have a major impact in this trial (although four of the six relapsers in this study had this polymorphism) (34). However, the larger phase 3 OPTIMIST-1 (35) and OPTIMIST-2 trials (36) showed that, with sofosbuvir and simeprevir, the presence of the Q80K substitution at baseline was associated with lower SVR rates with 12 weeks of therapy in patients with cirrhosis and lower SVR rates when treatment was shortened to 8 weeks in non-cirrhotic patients. Extending

therapy to 12 weeks in the non-cirrhotic group overcame the effect of the baseline Q80K polymorphism. Based on the COSMOS results, neither addition of ribavirin nor extended treatment duration to 24 weeks were evaluated in the OPTIMIST trials (35,36). Both of these strategies have proven useful to overcome resistance in other studies, and one wonders whether either approach would have improved SVR rates with this regimen.

Recently, pooled analyses of phase 2 and 3 trials of the second-wave NS5A inhibitor, elbasvir, and the second-generation protease inhibitor, grazoprevir, have demonstrated a role for ribavirin in select HCV GT1-infected populations. A pooled analysis of HCV GT1-infected patients with compensated cirrhosis demonstrated that including ribavirin and extending therapy from 12 to 16/18 weeks increased the SVR rate from 92% to 100% in the subset of non-responders to prior peginterferon plus ribavirin therapy (Table 1) (37). A similar numerical increase in SVR rate was observed when ribavirin was included and therapy was extended from 12 to 16/18 weeks in HCV GT1a-infected patients with on-treatment failure to prior therapy with peginterferon plus ribavirin with or without a first-generation protease inhibitor (90% versus 100%; Table 1) (38). Closer analysis shows again that the effect of ribavirin relates to overcoming the impact of baseline RASs. In both treatment-naive and treatment-experienced patients with GT1a infection, baseline NS5A RASs significantly reduced the likelihood of SVR. In the treatment-experienced population, extension of grazoprevir/elbasvir therapy from 12 to 16/18 weeks with the addition of ribavirin overcame the effect of baseline RASs, with 100% of patients achieving SVR, compared with 76% of those who received 12 weeks of therapy without ribavirin (39). Extension of treatment was unnecessary in those without baseline RASs, with similar response rates with 12 or 16/18 weeks of therapy with or without ribavirin (96% vs 100%) (39). The effect of adding ribavirin in treatment-naive patients was not analyzed; however, the FDA has recommended baseline NS5A RAS testing prior to starting grazoprevir/elbasvir in all patients with GT1a infection, with the recommendation to extend therapy to 16 weeks and add ribavirin in those who test positive. Notably, in a pooled analysis of non-cirrhotic, treatment-naive patients with GT1b infection, baseline RASs had no effect on response rates for 8 weeks of grazoprevir/elbasvir therapy with or without ribavirin (90% versus 94%; Table 1) (40). Collectively, these data suggest that ribavirin increases the barrier to resistance, which is particularly relevant for patients with GT1a infection receiving regimens that include DAAs with low barriers to resistance such as NS5A inhibitors, protease inhibitors and non-nucleoside NS5B inhibitors.

Optimizing therapy by shortening treatment duration in HCV GT1-infected patients

Recent data, particularly in patients with cirrhosis, have shown that adding ribavirin to DAA regimens may allow for shortened treatment durations without reducing SVR rates. As discussed above, a pooled analysis of phase 2 and 3 trials in HCV GT1-infected patients with cirrhosis receiving ledipasvir/sofosbuvir for 12 or 24 weeks showed that ribavirin can boost SVR rates in patients treated for 12 weeks, while ribavirin confers little additional benefit in those treated for 24 weeks, suggesting that ribavirin compensates for reducing the length of treatment (21). Combined with the results from the SIRIUS study (20), also discussed above, these data suggest a role for ribavirin in reducing the treatment duration of ledipasvir/sofosbuvir in treatment-experienced patients with cirrhosis (20,21).

Further insight into ribavirin's potential to shorten DAA treatment duration will come from the multitude of 'real-world' studies currently underway. Interim results from the HEPATHER French cohort study support trial data. The addition of ribavirin to 24 weeks of daclatasvir and sofosbuvir for HCV GT1-infected patients was of no clear benefit (SVR12 98% [61/62] with and 93% [172/184] without); however, with a 12-week course of treatment, the addition of ribavirin increased SVR rates from 85% (45/53) to 100% (11/11). Although these data support the concept that ribavirin may allow shorter treatment duration, the small number of patients and the non-randomized nature of this study limit interpretation of results (41).

Optimizing therapy in other HCV GT1-infected patient populations

In the interferon era, patients with very advanced liver disease were highly challenging to treat due to poor efficacy and increased toxicity. Consequently, there has been an urgent medical need for safer and more effective treatment options. Well-tolerated oral DAA therapies have changed the options for these patients dramatically, but results from clinical trials of DAA regimens have shown that, in many cases, ribavirin is still of benefit.

Decompensated liver disease and pre-liver transplant

Until recently, few data existed for patients with decompensated cirrhosis. Initial trials of ledipasvir/sofosbuvir (SOLAR-1/SOLAR-2) and daclatasvir and sofosbuvir (ALLY-1) included low-dose ribavirin and have shown SVR rates of >85% or >55% in patients with Child-Pugh B or C cirrhosis, respectively (42-44). It is unknown whether excluding ribavirin would have changed treatment outcomes. The phase 2 C-SALT study evaluated the efficacy and safety of elbasvir/grazoprevir without ribavirin in

Accepted Article

30 patients with HCV GT1 and Child-Pugh B cirrhosis, and showed an overall SVR rate of 90% (45). Whether adding ribavirin would confer additional benefit is unclear. The only study to look at the role of ribavirin in decompensated patients was the recently completed Phase 3, ASTRAL-4 study that investigated the efficacy and safety of the DAA combination sofosbuvir/velpatasvir (pan-genotypic NS5A inhibitor) with or without ribavirin in patients classified with Child-Pugh B cirrhosis (46). Numerically higher SVR12 rates were achieved in HCV GT1-infected patients receiving 12 weeks of sofosbuvir/velpatasvir with ribavirin (96%; 65/68) versus those without ribavirin (88%; 60/68) (46). Moreover, the study suggested that extending treatment duration to 24 weeks in the absence of ribavirin (92%; 65/71) may be less effective than addition of ribavirin to 12 weeks of sofosbuvir/velpatasvir treatment in patients with decompensated cirrhosis (46). These results may retrospectively vindicate the decision to perform the earlier SOLAR-1, -2, and ALLY-1 studies in decompensated patients only with ribavirin. Patients with decompensated cirrhosis tend to be more difficult to treat and have lower SVR rates compared with patients with compensated cirrhosis (47). The reasons for this are unclear; however, addition of ribavirin may be important to maximize SVR rates in this patient population. Of note, in ASTRAL-4, a weight-based ribavirin dose of 1000–1200 mg/day was used compared with a lower ribavirin starting dose of 600 mg in the SOLAR and ALLY-1 studies (increased doses as tolerated were used in SOLAR-1 and -2)(42-44,46).

For patients with detectable HCV at the time of transplant, post-operative recurrence of HCV in the graft is universal (48) and, therefore, HCV-infected patients on liver transplant waiting lists remain a population with high unmet medical need. Limited data are available for patients in the pre-transplant setting; however, a small phase 2 study of sofosbuvir plus ribavirin for 12 weeks demonstrated prevention of HCV recurrence in 70% (30/43) of patients with HCV-related liver cancer who achieved an HCV RNA of <25 IU/mL prior to transplant (49). Although addition of ribavirin is likely beneficial over sofosbuvir monotherapy, whether the use of a second DAA would achieve similar benefits is unknown. Ribavirin was again fairly well tolerated even in these patients with advanced cirrhosis.

Post-liver transplant

Similar to trials in patients with decompensated liver disease, most studies in post-liver transplant recipients have not been designed to formally evaluate ribavirin's role. In the post-transplant setting, SVR rates of 70% (28/40 patients) have been described with sofosbuvir plus ribavirin (50). Although these rates seem suboptimal compared to the non-transplant setting, it is important to remember that trials included patients with fibrosing cholestatic hepatitis and recurrent cirrhosis post-transplant. Trials of regimens that combine DAAs and ribavirin have shown higher

SVR rates in transplant recipients, including ledipasvir/sofosbuvir plus ribavirin, which yielded SVR rates of 95–98% (SOLAR-1 and SOLAR-2) (42,43), and daclatasvir and sofosbuvir plus ribavirin, which yielded SVR rates of 95% (ALLY-1) (44). To date, all trials of ledipasvir/sofosbuvir, and daclatasvir and sofosbuvir, have included ribavirin. Given concerns about tolerability, ribavirin has been started at a lower dose in the post-transplant setting (typically 600 mg daily) with no obvious clinical consequence; however, higher (or lower doses) have not been evaluated. In part 1 of the CORAL-1 study, an SVR rate of 97% was reported in 34 liver transplant recipients with HCV GT1 who received ombitasvir/paritaprevir/ritonavir and dasabuvir plus ribavirin for 24 weeks (51). Whether ribavirin plays an important role for HCV GT1-infected liver transplant recipients without cirrhosis has been evaluated in part 2 of the CORAL-I study (53). In part 2, HCV GT1b-infected patients who were either treatment-naïve or prior relapsers to peginterferon/ribavirin were treated with 24 weeks of ombitasvir/paritaprevir/ritonavir and dasabuvir without ribavirin. All 13 patients achieved SVR, reinforcing the high barrier to resistance in GT1b-infected patients that allows for the exclusion of ribavirin (53). Patients with GT1a infection and those with GT1b infection who were prior non-responders were treated with 24 weeks of ombitasvir/paritaprevir/ritonavir and dasabuvir with ribavirin; 26 of 27 (96%) achieved SVR (53).

The real-world effectiveness of sofosbuvir-containing regimens in the post-transplant setting, with or without ribavirin, is being evaluated in the observational HCV-TARGET study (54) and the French prospective CUPILT study (55). To date, an SVR4 rate of 91% (52/57 patients) has been described with simeprevir and sofosbuvir, compared with 82% (9/11 patients) with simeprevir and sofosbuvir plus ribavirin in the HCV-TARGET cohort (54). In the CUPILT study, treatment with daclatasvir and sofosbuvir for 12 or 24 weeks has yielded SVR12 rates of 97% (73/75) without ribavirin and 95% (52/55) with ribavirin (55). In both studies, the lack of randomization and the low patient numbers, particularly in the ribavirin-containing groups, limited any conclusions regarding whether there is a role for ribavirin in liver transplant patients as part of this regimen.

Renal impairment

Currently patients with severe renal impairment have limited treatment options and there remains urgent medical need to evaluate DAA regimens in these patients. Using ribavirin in this setting is problematic due to the renal excretion of ribavirin and its metabolites resulting in an increase in drug exposure and potential toxicities (56). However, a reduced daily dose of 200 mg of ribavirin can be administered to patients with severe renal impairment, including those who are undergoing hemodialysis (14). The RUBY-I study investigated the efficacy and safety of

ombitasvir/paritaprevir/ritonavir and dasabuvir with (HCV GT1a) and without (HCV GT1b) low-dose ribavirin for 12 weeks in patients with severe renal impairment or end-stage renal disease (57). Results show that 90% (18/20) of patients achieved an SVR. Of the two patients who failed to achieve an SVR, one GT1a-infected patient experienced virologic relapse and one patient died after the end of treatment due to reasons not attributed to DAAs or ribavirin (57). However, in patients with HCV GT1a infection and who received ribavirin, anemia was responsible for eight out of 13 patients requiring ribavirin dose interruption, and four requiring erythropoietin (58). No patient underwent a blood transfusion (58). Given ribavirin's relatively poor tolerability in patients with chronic kidney disease, and the relatively high SVR rates without ribavirin in patients with normal renal function, even those patients with GT1a (15,16,30,59,60), the role of ribavirin for GT1a-infected patients with chronic kidney disease is currently being evaluated in the ongoing RUBY-II study (61).

The large C-SURFER study demonstrated that the DAA combination of elbasvir/grazoprevir without ribavirin was well tolerated and achieved an SVR rate of 94% in HCV GT1-infected patients with chronic kidney disease, (62). These data suggest that ribavirin is not needed with elbasvir/grazoprevir to optimize efficacy in HCV GT1a-infected patients with severe renal impairment. The reason for the apparent capacity to omit ribavirin in GT1a-infected patients with renal failure but not, as in C-EDGE, patients with normal renal function (in whom baseline RASs had an adverse impact) (60,62), is unclear but may be related to the lower baseline HCV RNA levels seen in patients with advanced renal disease, somewhat mitigating the effect of baseline RASs in this population. Additional data focusing specifically on GT1a patients with renal failure and baseline RASs would be useful to definitively evaluate whether ribavirin is entirely dispensable in regimens lacking a nucleotide polymerase inhibitor in this setting.

Human immunodeficiency virus (HIV)/HCV co-infection

In patients co-infected with HIV/HCV, there is a general lack of head-to-head comparative data with and without ribavirin, and most ongoing clinical trials are currently evaluating ribavirin-free therapy (63-66). Although the reluctance to use ribavirin in co-infected patients may stem from concerns about additive drug toxicity with antiretroviral therapy, results in co-infected patients have been shown to be generally similar to those seen with HCV mono-infection, suggesting that ribavirin should play a similar clinical role in both populations. International guidelines recommend that HIV/HCV co-infected persons be treated and retreated the same as HCV-infected persons without HIV infection (22,67). Therefore, the addition of ribavirin may also be considered to maximize efficacy rates in specific subgroups of patients with HIV/HCV co-infection.

Optimizing therapy in patients infected with HCV genotypes other than GT1

Results from clinical trials until now have shown that ribavirin confers benefit in select patients with HCV GT1. To date, many of the same insights into ribavirin's role seen with HCV GT1 have been seen in those with other genotypes.

Genotype 2 or 3

Several phase 2 studies have provided insights into the importance of treating HCV GT2 and GT3 patients with ribavirin. The ELECTRON study evaluated the single DAA sofosbuvir plus ribavirin (weight-based [<75 kg, 1000 mg/day; ≥ 75 kg, 1200 mg/day] or reduced dose [800 mg/day]) for 8 to 12 weeks in treatment-naive and treatment-experienced patients (69). SVR rates in this study showed that durations of less than 12 weeks (8 weeks [64%] versus 12 weeks [100%]) or 12 weeks with a reduced ribavirin dose (weight-based [100%] versus low dose [60%]) may adversely impact efficacy in patients with HCV GT2 or GT3 (69). One small, phase 2, open-label study evaluated the DAA combination of daclatasvir and sofosbuvir for 24 weeks with and without ribavirin in treatment-naive patients with HCV GT2 and GT3 (70). Although SVR rates were numerically higher in those who received ribavirin (100%) than in those who did not (93%), with only 14 patients per arm, it is difficult to evaluate the true value of ribavirin in this population (70). The phase 3 ALLY-3 and ALLY-3+ trials in HCV GT3-infected patients evaluated daclatasvir and sofosbuvir for 12 weeks without ribavirin and for 12 or 16 weeks with ribavirin, respectively. Among patients with cirrhosis, numerically higher SVR rates were achieved in ALLY3+ with both the 12- and the 16-week regimens of daclatasvir and sofosbuvir plus ribavirin (83% [15/18] and 89% [16/18], respectively) versus the 12-week regimen without ribavirin (65% [22/34]) in ALLY-3 (71). Further analysis showed that the effect of ribavirin on SVR rates was related to overcoming the impact of baseline RASs. However, an interim analysis evaluating the efficacy of daclatasvir and sofosbuvir with and without ribavirin in clinical practice has shown that very high SVR rates are achieved without ribavirin, including in patients with GT3 infection and compensated cirrhosis, and the addition of ribavirin does not confer additional benefit (72).

Furthermore, it appears that most ongoing trials investigating second-wave DAA combinations, such as the ASTRAL and SURVEYOR studies evaluating the efficacy and safety of sofosbuvir/velpatasvir and ABT-493 (NS3/4A protease inhibitor) plus ABT-530 (NS5A inhibitor), respectively, in patients with HCV GT2 and 3 infection are doing so without the use of ribavirin (73-75).

Patients with HCV GT2 and GT3 infection were treated with sofosbuvir/velpatasvir for 12 weeks in the ASTRAL-2 and ASTRAL-3 studies, respectively(73). Although the effect of ribavirin was not assessed in these studies, high SVR rates were achieved in

HCV GT2-infected patients (99%; 133/134); however, relatively low SVR rates were observed in specific patient populations in the ASTRAL-3 study. Overall, 95% (264/277) of HCV GT3-infected patients achieved an SVR, with treatment-experienced patients with and without cirrhosis achieving numerically lower SVR rates of 89% (33/37) and 91% (31/34), respectively (73). In a pooled analysis of the ASTRAL studies that included GT3-infected patients in ASTRAL-3, the SVR rate in patients with GT3 infection was numerically lower in those with baseline NS5A RASs versus those without (88% [28/32] versus 97% [235/242]) (76). Although the use of ribavirin has not yet been studied in this population, the AASLD/IDSA guidance document has recently recommended that ribavirin be added to sofosbuvir/velpatasvir for 12 weeks in all GT3 patients with cirrhosis, and treatment-experienced non-cirrhotic patients, who have baseline Y93 substitutions (23).

Genotype 4

A small number of HCV GT4-infected patients were included in the phase 3 studies of elbasvir/grazoprevir, C-EDGE (60), and C-SCAPE (77). Initial observations suggest that ribavirin may confer benefit by maximizing SVR rates. C-EDGE enrolled treatment-experienced patients with and without cirrhosis, and irrespective of treatment duration, SVR rates were higher for patients treated with elbasvir/grazoprevir plus ribavirin compared with the same regimen without ribavirin (12 weeks, 93% [14/15] versus 78% [7/9]; 16 weeks, 100% [8/8] versus 60% [3/5], respectively) (60). Twenty further treatment-naïve HCV GT4 patients without cirrhosis were enrolled in C-SCAPE, and treatment with elbasvir/grazoprevir plus ribavirin yielded similar SVR rates (100%, 10/10) compared with those treated without ribavirin (90%, 9/10) (77). Larger studies are needed to confirm ribavirin's role in reducing virologic failure in HCV GT4-infected patients with elbasvir/grazoprevir and to evaluate whether specific patient subgroups are likely to require ribavirin (e.g. those with NS5A baseline resistance).

Combination therapy with ombitasvir/paritaprevir/ritonavir also benefits from the addition of ribavirin in patients with HCV GT4 (78). In the PEARL-I study, following treatment with 12 weeks of ombitasvir/paritaprevir/ritonavir, 91% (40/44) of treatment-naïve non-cirrhotic patients achieved an SVR compared with 100% (42/42) in those treated with the addition of ribavirin (78). These data suggest that ribavirin may reduce virologic failure rates in HCV GT4-infected patients.

Interestingly, all three patients who experienced virologic failure were infected with subtype 4d and all had RASs present at the time of virologic failure (78). Adding ribavirin to ombitasvir/paritaprevir/ritonavir may act in preventing the emergence of RASs and removes HCV GT4 subtype-specific responses to therapy. Furthermore, 100% (49/49) of treatment-experienced, non-cirrhotic patients achieved an SVR with

12 weeks of ombitasvir/paritaprevir/ritonavir plus ribavirin, leading to the recent approval of this regimen for HCV GT4; a ribavirin-free regimen was not explored (78). A recent study evaluating the efficacy and safety of ledipasvir/sofosbuvir for 12 weeks in treatment-naive and -experienced HCV GT4-infected patients with and without cirrhosis reported SVR rates of 93% (79). The role of ribavirin was not evaluated (79).

Improved safety and tolerability of ribavirin in combination with interferon-free regimens

A wealth of clinical experience has been amassed with ribavirin over the past 30 years. However, recent data from large, randomized trials of some DAA regimens with and without ribavirin have shown that the safety profile of ribavirin relies heavily on the medications with which it is co-administered. Thus, the AE profile of ribavirin warrants a full re-evaluation in the absence of interferon.

Interferon/peginterferon and ribavirin regimens for chronic HCV had poor tolerability profiles, with relatively high treatment discontinuation rates and declines in hemoglobin to <10 g/dL (Table 2) (1,2,80). The introduction of first-generation DAAs, boceprevir and telaprevir, to peginterferon plus ribavirin regimens boosted SVR rates, but was associated with even worse tolerability profiles (3-7). Current interferon-free DAA regimens are relatively well-tolerated, and while adding ribavirin to these DAA regimens is generally associated with a slightly higher rate of some AEs than ribavirin-free regimens (15,16,30,31,81), this does not appear to affect patients' ability to complete treatment. With the interferon-free, all-oral DAA regimens, discontinuation rates due to AEs are typically below 3%, both with and without ribavirin (Table 2) (15,16,30,31,70,81). AEs (e.g. fatigue, headache, nausea, cough, rash, dyspepsia, insomnia, and dyspnea; Fig. 1C, 1D) and serious AEs (Table 2) generally occur much less frequently with interferon-free DAA regimens (15,16,30,31,70,81) versus combined interferon/peginterferon and ribavirin regimens (1,2) and boceprevir- and telaprevir-based regimens with peginterferon (3-7).

As with interferon-containing regimens plus ribavirin, the most common hematologic AE in patients who received the newer DAAs plus ribavirin was anemia. However, both the frequency and clinical severity of anemia is greatly reduced compared with what was observed in the interferon era, and also the frequency of anemia appears to vary based on the DAA regimen (Table 2).

Data from trials of DAA regimens have demonstrated that patients receiving ribavirin that experienced hemoglobin declines have been able to undergo ribavirin dose modification or discontinuation without negatively impacting SVR rates. For example, ribavirin dose modifications occurred in 7.7% (n=2044) of patients in a

safety analysis of ombitasvir/paritaprevir/ritonavir plus dasabuvir, but SVR rates were 98.5% and 96.0% in patients with and without ribavirin dose modifications, respectively (82). This finding is also consistent in patients with cirrhosis: an SVR rate of 100% was achieved in those who received a ribavirin dose modification in the TURQUOISE-II study (32).

Recently, patient-reported outcomes (PROs), including health-related quality of life and work productivity, have been reported for the phase 3 ION-1, ION-2, and ION-3 trials of ledipasvir/sofosbuvir with or without ribavirin that are discussed above (83). Although patients receiving ledipasvir/sofosbuvir without ribavirin showed significant improvements ($p < 0.001$) in PROs during treatment, those receiving treatment with ribavirin had significant ($p < 0.001$) declines in PROs during treatment; however, among patients who achieved SVR12, similar improvements in PROs were observed for both treatment groups post SVR12.

Insights into ribavirin's mechanism of action

Despite its long-standing use, the antiviral mechanism of action of ribavirin remains poorly understood. Multiple mechanisms have been proposed including inosine monophosphate dehydrogenase inhibition (84,85), promotion of a Th1 immune response (84,86-88), direct inhibition of the HCV polymerase (89), stimulation of interferon-stimulated genes (90), and mutagenesis leading to error catastrophe (91). Although there is some experimental evidence supporting each hypothesis, definitive proof of one mechanism of action is lacking. The lack of experimental models of antiviral relapse, the main target of the clinical effect of ribavirin, makes studies challenging to perform. The clinical data with DAAs have shown that ribavirin delays or possibly prevents the emergence of antiviral resistance and reduces relapse after therapy. These two effects may be linked as most cases of relapse are associated with replication of HCV resistant to one or more of the DAAs used in a given regimen.

Of the proposed theories, mutagenesis by ribavirin is the most compatible with the clinical effects seen. Ribavirin is a guanosine analogue, but unlike most nucleoside/nucleotide analogues, insertion of ribavirin into a nascent HCV genome does not lead to chain termination. Elongation with incorporated ribavirin is able to proceed; however, rather than pair with the natural base, ribavirin incorporation leads to G to U and U to G transitions. These mutations may have fitness effects leading to negative selection of HCV virions able to incorporate ribavirin and, ultimately over time, limiting the quasispecies variability of the circulating virus. Reduced viral diversity may limit the escape capacity of the virus and hence the emergence of resistance in the setting of selective pressure from one or more DAAs.

The restricted quasispecies variability may also limit compensatory mutations to overcome fitness deficits in resistant variants. Deep sequencing data support a mutagenic effect of ribavirin, as does mathematical modeling (92,93). Although ribavirin may act through multiple mechanisms, how the other proposed mechanisms of action would affect viral relapse and/or the emergence of resistance is less clear. The immunomodulatory functions of ribavirin have been recently comprehensively reviewed (94).

Conclusion

In the all-oral DAA era, there is still an important role for ribavirin in HCV treatment, particularly in the setting of DAAs with a low barrier to resistance, or in patients with features that make them hard to cure. Ribavirin delays or prevents the emergence of resistance, ultimately leading to a lower relapse rate and higher chance of SVR. Ribavirin also allows for shortening of therapy, particularly in patients with cirrhosis, without sacrificing efficacy. However, most data in support of a role for ribavirin in the all-oral DAA era are from small studies or subgroups that lack statistical significance. Ribavirin is relatively well tolerated as part of all-oral DAA regimens and the frequency and severity of anemia is considerably reduced and easy to manage in the absence of interferon. While ribavirin's mechanism(s) of action remain elusive, it has proven harder to replace than expected and, for the time being, continues to play a useful role in HCV therapy.

References

- [1] McHutchison J G, Gordon S C, Schiff E R, et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. *N Engl J Med* 1998; 339: 1485-92.
- [2] Fried M W, Shiffman M L, Reddy K R, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. *N Engl J Med* 2002; 347: 975-82.
- [3] Hezode C, Forestier N, Dusheiko G, et al. Telaprevir and peginterferon with or without ribavirin for chronic HCV infection. *N Engl J Med* 2009; 360: 1839-50.
- [4] Kwo P Y, Lawitz E J, McCone J, et al. Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial. *Lancet* 2010; 376: 705-16.

- [5] McHutchison J G, Manns M P, Muir A J, et al. Telaprevir for previously treated chronic HCV infection. *N Engl J Med* 2010; 362: 1292-303.
- [6] Poordad F, McCone J, Jr, Bacon B R, et al. Boceprevir for untreated chronic HCV genotype 1 infection. *N Engl J Med* 2011; 364: 1195-206.
- [7] Bacon B R, Gordon S C, Lawitz E, et al. Boceprevir for previously treated chronic HCV genotype 1 infection. *N Engl J Med* 2011; 364: 1207-17.
- [8] Poordad F, Lawitz E, Reddy K R, et al. Effects of ribavirin dose reduction vs erythropoietin for boceprevir-related anemia in patients with chronic hepatitis C virus genotype 1 infection--a randomized trial. *Gastroenterology* 2013; 145: 1035,1044.e5.
- [9] Di Bisceglie A M, Conjeevaram H S, Fried M W, et al. Ribavirin as therapy for chronic hepatitis C. A randomized, double-blind, placebo-controlled trial. *Ann Intern Med* 1995; 123: 897-903.
- [10] Camps J, Garcia N, Riezu-Boj J I, Civeira M P, Prieto J. Ribavirin in the treatment of chronic hepatitis C unresponsive to alfa interferon. *J Hepatol* 1993; 19: 408-12.
- [11] Dusheiko G, Main J, Thomas H, et al. Ribavirin treatment for patients with chronic hepatitis C: results of a placebo-controlled study. *J Hepatol* 1996; 25: 591-8.
- [12] Gara N, Ghany M G. What the infectious disease physician needs to know about pegylated interferon and ribavirin. *Clin Infect Dis* 2013; 56: 1629-36.
- [13] FDA. REBETOL (ribavirin USP) Prescribing Information. 1998; 2015.
- [14] FDA. MODERIBA (ribavirin) US Prescribing Information. 2002; 2015.
- [15] Afdhal N, Zeuzem S, Kwo P, et al. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. *N Engl J Med* 2014; 370: 1889-98.
- [16] Afdhal N, Reddy K R, Nelson D R, et al. Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. *N Engl J Med* 2014; 370: 1483-93.
- [17] Kowdley K V, Gordon S C, Reddy K R, et al. Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis. *N Engl J Med* 2014; 370: 1879-88.
- [18] Gilead Sciences. Harvoni US Prescribing Information. 2015; 2015.
- [19] Gilead Sciences. Harvoni EU Summary of Product Characteristics. 2015; 2015.

[20] Bourliere M, Bronowicki J, De Ledinghen V, et al. Ledipasvir-sofosbuvir with or without ribavirin to treat patients with HCV genotype 1 infection and cirrhosis non-responsive to previous protease-inhibitor therapy: a randomised, double-blind, phase 2 trial (SIRIUS). *Lancet Infectious Diseases* 2015; 15: 397-404.

[21] Reddy K, Bourlière M, Sulkowski M, et al. Ledipasvir and sofosbuvir in patients with genotype 1 hepatitis C virus infection and compensated cirrhosis: An integrated safety and efficacy analysis. *Hepatology* 2015; 62: 79-86.

[22] European Association for the Study of the Liver. EASL Recommendations on Treatment of Hepatitis C 2015. *Journal of Hepatology* 2015; 63: 199-236.

[23] AASLD-IDSA Guidance Panel. HCV Guidance: Recommendations for Testing, Managing, and Treating Hepatitis C. July 6, 2016; 2016.

[24] Curry MP, Bacon B, Flamm SL, et al. Effectiveness of 12 or 24 week LDV/SOF and 12 week LDV/SOF + RBV in treatment-experienced patients with cirrhotic, genotype 1 Hepatitis C: Real-world experience from the TRIO Network (poster presentation) *Hepatology* 2015; 62 (Suppl): 755A.

[25] Sarrazin C, Dvory-Sobol H, Svarovskaia E, et al. The Prevalence and the Effect of HCV NS5A Resistance-Associated Variants in Patients With Compensated Cirrhosis Treated With Ledipasvir/Sofosbuvir ± RBV. *Journal of hepatology* 2015; 62 (Suppl 2): S620 (Poster presentation).

[26] Feld J J, Kowdley K V, Coakley E, et al. Treatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. *N Engl J Med* 2014; 370: 1594-603.

[27] Zeuzem S, Jacobson I M, Baykal T, et al. Retreatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. *N Engl J Med* 2014; 370: 1604-14.

[28] AbbVie. Viekira Pak (ombitasvir, paritaprevir, and ritonavir tablets; dasabuvir tablets), co-packaged for oral use US Prescribing Information. 2016; 2016.

[29] AbbVie. Viekirax Summary of Product Characteristics. 2016; 2016.

[30] Ferenci P, Bernstein D, Lalezari J, et al. ABT-450/r-ombitasvir and dasabuvir with or without ribavirin for HCV. *N Engl J Med* 2014; 370: 1983-92.

[31] Andreone P, Colombo M G, Enejosa J V, et al. ABT-450, ritonavir, ombitasvir, and dasabuvir achieves 97% and 100% sustained virologic response with or without ribavirin in treatment-experienced patients with HCV genotype 1b infection. *Gastroenterology* 2014; 147: 359-65.

[32] Poordad F, Hezode C, Trinh R, et al. ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis. *N Engl J Med* 2014; 370: 1973-82.

[33] Feld J J, Moreno C, Trinh R, et al. Sustained Virologic Response of 100% in HCV Genotype 1b Patients with Cirrhosis Receiving Ombitasvir/Paritaprevir/r and Dasabuvir for 12 Weeks. *J Hepatol* 2016; 64: 301-7.

[34] Lawitz E, Sulkowski M S, Ghalib R, et al. Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naïve patients: the COSMOS randomised study. *Lancet* 2014; 384: 1756-65.

[35] Kwo P, Gitlin N, Nahass R, et al. A phase 3, randomised, open-label study to evaluate the efficacy and safety of 8 and 12 weeks of simeprevir (SMV) plus sofosbuvir (SOF) in treatment-naïve and -experienced patients with chronic HCV genotype 1 infection without cirrhosis: OPTIMIST-1. *Journal of Hepatology* 2015; 62 (Suppl 2): S270 (Latebreaker poster presentation LP14).

[36] Lawitz E, Matusow G, DeJesus E, et al. A phase 3, open-label, single-arm study to evaluate the efficacy and safety of 12 weeks of simeprevir (SMV) plus sofosbuvir (SOF) in treatment-naïve or -experienced patients with chronic HCV genotype 1 infection and cirrhosis: Optimist-2. *Journal of Hepatology* 2015; 62 (Suppl 2): S264,S265 (Latebreaker poster presentation LP04).

[37] Jacobson IM, Lawitz E, Kwo PY, et al. An Integrated Analysis of 402 Compensated Cirrhotic Patients With HCV Genotype (GT) 1, 4 or 6 Infection Treated With Grazoprevir/Elbasvir (oral presentation). *Hepatology* 2015; 62 (Suppl): 229A.

[38] Thompson AJ, Zeuzem S, Rockstroh JK, et al. The Combination of Grazoprevir and Elbasvir ± RBV Is Highly Effective for the Treatment of GT1a-Infected Patients (poster presentation). *Hepatology* 2015; 62 (Suppl): 556-557A.

[39] Jacobson IM, Asante-Appiah E, Wong P, et al. Prevalence and Impact of Baseline NSA Resistance Associated Variants (RAVs) on the Efficacy of Elbasvir/Grazoprevir (EBR/GZR) Against GT1a Infection (late-breaking poster presentation). *Hepatology* 2015; 62 (Suppl): 1393-1394A.

[40] Serfaty L, Zeuzem S, Vierling JM, et al. High Efficacy of the Combination HCV Regimen Grazoprevir and Elbasvir for 8 or 12 Weeks With or Without Ribavirin in Treatment-Naïve, Noncirrhotic HCV GT1b-Infected Patients: An Integrated Analysis (poster presentation). *Hepatology* 2015; 62 (Suppl): 555-556A.

[41] Pol S, Bourliere M, Lucier S, et al. Safety and efficacy of the combination daclatasvir-sofosbuvir in HCV genotype 1-mono-infected patients from the

French observational cohort ANRS CO22 HEPATHER. *Journal of Hepatology* 2015; 62 (Suppl 2): S258-9.

[42] Charlton M, Everson G, Flamm S, et al. Ledipasvir and sofosbuvir plus ribavirin for treatment of HCV infection with advanced liver disease. *Gastroenterology* 2015; 149: 649-59.

[43] Manns M, Forns X, Samuel D, et al. Ledipasvir/sofosbuvir with ribavirin is safe and efficacious in decompensated and post liver transplantation patients with HCV infection: preliminary results of the prospective SOLAR 2 trial. *Journal of hepatology* 2015; 62 (Suppl): S187-8.

[44] Poordad F, Schiff ER, Vierling JM, Landis C, Fontana RJ, Yang R, McPhee F, Hughes EA, Noviello S, Swenson ES. Daclatasvir with sofosbuvir and ribavirin for HCV infection with advanced cirrhosis or post-liver transplant recurrence. *Hepatology* 2016: E-pub ahead of print.

[45] Jacobson I, Poordad F, Firpi-Morell R, et al. Efficacy and safety of grazoprevir and elbasvir in hepatitis C genotype 1-infected patients with child-pugh class B cirrhosis (C-SALT part A). *Journal of Hepatology* 2015; 62 (Suppl 2): S193,S194 (Oral presentation).

[46] Curry M P, O'Leary J G, Bzowej N H, et al. Sofosbuvir and velpatasvir for HCV in patients with decompensated cirrhosis. *New England Journal of Medicine* 2015; 373: 2618-28.

[47] Kwo P, Agrawal S. Treating hepatitis C virus in patients with decompensated cirrhosis: Why is it so difficult and does a sustained response rate rescue the patient from liver transplantation? *Clinical Liver Disease* 2015; 6: 133-5.

[48] Wright TL, Donegan E, Hsu HH, Ferrell L, Lake JR, Kim M, Combs C, Fennesy S, Roberts JP, Ascher NL. Recurrent and acquired hepatitis C viral infection in liver transplant recipients. *Gastroenterology* 1992; 103: 317-22.

[49] Curry M P, Forns X, Chung R T, et al. Sofosbuvir and ribavirin prevent recurrence of HCV infection after liver transplantation: an open-label study. *Gastroenterology* 2015; 148: 100,107.e1.

[50] Charlton M, Gane E, Manns M P, et al. Sofosbuvir and ribavirin for treatment of compensated recurrent hepatitis C virus infection after liver transplantation. *Gastroenterology* 2015; 148: 108-17.

[51] Kwo P Y, Mantry P S, Coakley E, et al. An interferon-free antiviral regimen for HCV after liver transplantation. *N Engl J Med* 2014; 371: 2375-82.

[52] Poordad F, Schiff E, Vierling J, et al. Daclatasvir, sofosbuvir, and ribavirin combination for HCV patients with advanced cirrhosis or posttransplant recurrence: Phase 3 ALLY-1 study. *Journal of hepatology* 2015; 62 (Suppl 2): S261-2.

[53] Mantry P, Brown Jr R, Enejosa JV, Berenguer M, Kwo PY, Agarwal K et al. Ombitasvir/paritaprevir/r and dasabuvir with or without ribavirin for patients with post-transplant HCV recurrence. *Hepatology* 2015; 62 (Suppl 1): 742A (poster presentation).

[54] Brown R S, Reddy K, O'Leary J G, et al. Safety and Efficacy of New DAA-based Therapy for Hepatitis C Post-Transplant: Interval Results from the HCV-TARGET Longitudinal, Observational Study. *Hepatology* 2014; 60: LB-4.

[55] Coilly A, Fougerou C, De Ledinghen V, et al. The association of sofosbuvir and daclatasvir for treating severe recurrence of HCV infection after liver transplantation: Results from a large french prospective multicentric ANRS CO23 CUPILT cohort. *Journal of hepatology* 2015; 62 (Suppl): S187,S188 (Oral presentation).

[56] University of Liverpool. Hepinteractions website. 2015; 2015.

[57] Pockros P, Reddy K, Mantry P, et al. RUBY-I: ombitasvir/paritaprevir/ritonavir + dasabuvir +/- ribavirin in non-cirrhotic HCV genotype 1-infected patients with severe renal impairment or end-stage renal disease. *Hepatology* 2015; 62 (Suppl): 716,717A (poster presentation).

[58] Pockros P, Reddy KR, Mantry P, et al. Safety of ombitasvir/paritaprevir/ritonavir plus dasabuvir for treating HCV GT1 infection in patients with severe renal impairment or end-stage renal disease: The Ruby-I study. *Journal of hepatology* 2015; 62 (Suppl 2): S257.

[59] Lawitz E, Gane E, Pearlman B, et al. Efficacy and safety of 12 weeks versus 18 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin for hepatitis C virus genotype 1 infection in previously untreated patients with cirrhosis and patients with previous null response with or without cirrhosis (C-WORTHY): a randomised, open-label phase 2 trial. *Lancet* 2014.

[60] Kwo P, Gane E, Peng C, et al. Efficacy and safety of grazoprevir/elbasvir +/- RBV for 12 or 16 weeks in patients with HCV G1, G4 or G6 infection who previously failed peginterferon/RBV: C-EDGE treatment-experienced. *Journal of Hepatology* 2015; 62 (Suppl 2): S674-5.

[61] clinicaltrials.gov. Ombitasvir/paritaprevir/ritonavir with or without dasabuvir in adults with genotype 1a or genotype 4 chronic hepatitis C virus (HCV) infection, with severe kidney impairment or end stage kidney disease. *Journal of hepatology* 2015; 2015.

[62] Roth D, Nelson D R, Bruchfeld A, et al. Grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and stage 4-5 chronic kidney disease (the C-SURFER study): a combination phase 3 study. *Lancet* 2015; 386: 1537-45.

[63] Naggie S, Cooper C, Saag M, et al. Ledipasvir and sofosbuvir for HCV in patients coinfecting with HIV-1. *New England Journal of Medicine* 2015; [Epub ahead of print].

[64] Rockstroh J, Nelson M, Katlama C, et al. C-edge co-infected: phase 3 study of grazoprevir/elbasvir in patients with HCV/HIV. *Journal of Hepatology* 2015; 62 (Suppl 2): S675.

[65] Wyles D L, Ruane P J, Sulkowski M S, et al. Daclatasvir plus Sofosbuvir for HCV in Patients Coinfected with HIV-1. *N Engl J Med* 2015; 373: 714-25.

[66] clinicaltrials.gov. A two part, open-label study to evaluate the safety and effectiveness of ABT-450/r/ABT-267 or ABT-450/r/ABT-267 and ABT-333 given with or without a drug called ribavirin in people with both hepatitis C virus genotype 1 or 4 infection and human immunodeficiency virus, type 1 infection (TURQUOISE-I). 2015; 2015.

[67] AASLD/IDSA HCV guidance panel. HCV Guidance: Recommendations for Testing, Managing, and Treating Hepatitis C. *Hepatology* 2015; 62: 932-54.

[68] Gower E, Estes C, Blach S, Razavi-Shearer K, Razavi H. Global epidemiology and genotype distribution of the hepatitis C virus infection. *J Hepatol* 2014; 61: S45-57.

[69] Gane E, Stedman C, Hyland R, et al. Once daily sofosbuvir (GS-7977) plus ribavirin in patients with HCV genotypes 1,2, and 3: the ELECTRON trial. *Hepatology* 2012; 56 (Suppl): 306A-7A.

[70] Sulkowski M S, Gardiner D F, Rodriguez-Torres M, et al. Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection. *N Engl J Med* 2014; 370: 211-21.

[71] Kowdley K, Angus P, Bernstein D, et al. All-oral treatment with daclatasvir plus sofosbuvir ± ribavirin in HCV genotype 3-infected patients with advanced fibrosis or cirrhosis: an analysis of ALLY-3 and ALLY-3+ (poster presentation). *J Hepatol* 2016; 64 (Suppl 2): 739.

[72] Welzel TM, Petersen J, Ferenci P, et al. Safety and efficacy of daclatasvir plus sofosbuvir with or without ribavirin for the treatment of chronic HCV genotype 3 infection: Interim results of a multicenter European compassionate use program (oral presentation) *Hepatology* 2015; 62 (Suppl): 225-226A.

[73] Foster G, Afdhal N, Roberts SK, et al. Sofosbuvir and velpatasvir for HCV genotype 2 and 3 infection. *New England Journal of Medicine* 2015; 373: 2608-17.

[74] Kwo P, Bennett M, Wang S, Vargas HE, Wyles D, Scott Overcash J, Ruane P, Maliakkal B, Siddique A, et al. **SURVEYOR-II: High SVR4 Rates**

Achieved With the Next Generation NS3/4A Protease Inhibitor ABT-493 and NS5A Inhibitor ABT-530 in Non-Cirrhotic Treatment-Naïve and Treatment-Experienced Patients With HCV Genotype 3 Infection. *Hepatology* 2015; 62 (Suppl): 337,338A (oral presentation).

[75] Wyles D, Sulkowski M, Wang S, Bennet M, Vargez HE, Scott Overcash J, Maliakkal B, Siddique A, et al. **SURVEYOR-II**: High SVR4 Rates Achieved With the Next Generation NS3/4A Protease Inhibitor ABT-493 and NS5A Inhibitor ABT-530 in Non-Cirrhotic Treatment-Naïve and Treatment-Experienced Patients With HCV Genotype 2 Infection. *Hepatology* 2015; 62 (Suppl): 339,340A (oral presentation).

[76] Hezode C, Reau N, Svarovskaia E, et al. Resistance analysis in 1284 patients with genotype 1 to 6 HCV infection treated with sofosbuvir/velpatasvir in the phase 3 ASTRAL-1, ASTRAL-2, ASTRAL-3 and ASTRAL-4 studies. *Journal of Hepatology* 2016; 64 (Suppl 2): S399,S400 (Poster presentation).

[77] Brown A, Hezode C, Zuckerman E, et al. C-SCAPE: Efficacy and safety of 12 weeks of grazoprevir +/- elbasvir +/- ribavirin in patients with HCV GT2, 4, 5 or 6 infection. *Journal of Hepatology* 2015; 62 (Suppl 2): S619.

[78] Hezode C, Asselah T, Reddy K, et al. Ombitasvir plus paritaprevir plus ritonavir with or without ribavirin in treatment-naïve and treatment-experienced patients with genotype 4 chronic hepatitis C virus infection (PEARL-I): a randomised, open-label trial. *Lancet* 2015; 385: 2502-9.

[79] Abergel A, Loustaud-Ratti V, Metivier S, et al. Ledipasvir/sofosbuvir treatment results in high SVR rates in patients with chronic genotype 4 and 5 HCV infection. *Journal of Hepatology* 2015; 62 (Suppl 2): S219-20.

[80] Poynard T, Marcellin P, Lee S S, et al. Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT). *Lancet* 1998; 352: 1426-32.

[81] Gane E J, Stedman C A, Hyland R H, et al. Efficacy of nucleotide polymerase inhibitor sofosbuvir plus the NS5A inhibitor ledipasvir or the NS5B non-nucleoside inhibitor GS-9669 against HCV genotype 1 infection. *Gastroenterology* 2014; 146: 736,743.e1.

[82] Fried M, Di Bisceglie A M, Vierling J, et al. Safety of ABT-450/Ritonavir/Ombitasvir + Dasabuvir With or Without Ribavirin in HCV Genotype 1-infected Patients: Results From Phase 2 and 3 Trials. *Hepatology* 2014; 60: 1145A.

[83] Younossi Z M, Stepanova M, Marcellin P, et al. Treatment with ledipasvir and sofosbuvir improves patient-reported outcomes: Results from the ION-1, -2, and -3 clinical trials. *Hepatology* 2015; 61: 1798-808.

[84] Lau J Y, Tam R C, Liang T J, Hong Z. Mechanism of action of ribavirin in the combination treatment of chronic HCV infection. *Hepatology* 2002; 35: 1002-9.

[85] Lanford R E, Chavez D, Guerra B, et al. Ribavirin induces error-prone replication of GB virus B in primary tamarin hepatocytes. *J Virol* 2001; 75: 8074-81.

[86] Rahman F, Heller T, Sobao Y, et al. Effects of antiviral therapy on the cellular immune response in acute hepatitis C. *Hepatology* 2004; 40: 87-97.

[87] Feld J J, Hoofnagle J H. Mechanism of action of interferon and ribavirin in treatment of hepatitis C. *Nature* 2005; 436: 967-72.

[88] Feld J J. Is there a role for ribavirin in the era of hepatitis C virus direct-acting antivirals? *Gastroenterology* 2012; 142: 1356-9.

[89] Maag D, Castro C, Hong Z, Cameron C E. Hepatitis C virus RNA-dependent RNA polymerase (NS5B) as a mediator of the antiviral activity of ribavirin. *J Biol Chem* 2001; 276: 46094-8.

[90] Werner J, Serti E, Chepa-Lotrea X, et al. Ribavirin improves the IFN- γ response of natural killer cells to IFN-based therapy of hepatitis C infection. *Hepatology* 2014; 60: 1160-9.

[91] Crotty S, Cameron C E, Andino R. RNA virus error catastrophe: direct molecular test by using ribavirin. *Proc Natl Acad Sci U S A* 2001; 98: 6895-900.

[92] Dietz J, Schelhorn S E, Fitting D, et al. Deep sequencing reveals mutagenic effects of ribavirin during monotherapy of hepatitis C virus genotype 1-infected patients. *J Virol* 2013; 87: 6172-81.

[93] Dixit N M, Layden-Almer J E, Layden T J, Perelson A S. Modelling how ribavirin improves interferon response rates in hepatitis C virus infection. *Nature* 2004; 432: 922-4.

[94] Mondelli M U. The multifaceted functions of ribavirin: antiviral, immunomodulator, or both? *Hepatology* 2014; 60: 1126-9.

[95] Reddy K R, Everson G T, Flamm S L, et al. Ledipasvir/Sofosbuvir with Ribavirin for the Treatment of HCV in Patients with Post Transplant Recurrence: Preliminary Results of a Prospective, Multicenter Study. *Hepatology* 2014; 60: 200A.

[96] Kowdley K V, Lawitz E, Poordad F, et al. Phase 2b trial of interferon-free therapy for hepatitis C virus genotype 1. *N Engl J Med* 2014; 370: 222-32.

Table 1: Comparative data evaluating the role of ribavirin in the treatment of GT1 HCV.

Patient characteristics			Treatment regimen			SVR, n/N (%)
Prior treatment	Genotype	Cirrhosis, Y/N (%)	First author/study name	Treatment	Duration	
Naive	1	Y (5) ^{*,‡}	McHutchinson et al., 1998 (1)	IFN versus IFN + RBV	24 weeks	3/167 (2) versus 26/164 (16)
					48 weeks	11/162 (7) versus 46/166 (28)
Naive	1,4,5,6	Y (4) ^{*,‡}	Poynard et al., 1998 (80)	IFN versus IFN + RBV	48 weeks	20/179 (11) versus 56/180 (31)
Naive	1	Y (13) ^{*,‡}	Fried et al., 2002 (2)	PegIFN versus PegIFN + RBV	48 weeks	30/145 (21) versus 138/297 (46)
Naive	1	Y (16)	ION-1 (15)	LDV/SOF versus LDV/SOF + RBV	12 weeks	211/214 (99) versus 211/217 (97)
					24 weeks	212/217 (98) versus 215/217 (99)
Naive	1	N	ION-3 (17)	LDV/SOF versus LDV/SOF + RBV	8 weeks	202/215 (94) versus 201/216 (93)
PegIFN ± NS3/4A PI	1	Y (20)	ION-2 (16)	LDV/SOF versus LDV/SOF + RBV	12 weeks	102/109 (94) versus 107/111 (96)
					24 weeks	108/109 (99) versus 110/111 (99)

PegIFN ± RBV or naive	1	Y (100) [‡]	Reddy et al., 2015 (21)	LDV/SOF versus LDV/SOF + RBV	12 weeks	109/118 (92) versus 196/204 (96)
					24 weeks	103/133 (98) versus 58/58 (100)
PegIFN/RBV; PegIFN/RBV + PI or naive	1 or 4	Y (67)	SOLAR-1 (42)*	LDV/SOF + RBV	12 weeks	152/168 (90)
					24 weeks	151/163 (93)
Experienced or naive	1 or 4	Y	SOLAR-2 (43)	LDV/SOF + RBV	12 weeks post-transplant	82/86 (95)
					24 weeks post-transplant	64/65 (98)
					12 weeks pre/post-transplant [¶]	61/72 (85)
					24 weeks pre/post-transplant [¶]	60/68 (88)
Experienced or naive	1, 4	Y (50)	Reddy et al., 2014 (95)	LDV/SOF + RBV	12 weeks	103/112 (92)
					24 weeks	96/102 (94)
PegIFN/RBV + PI	1	Y (100)	SIRIUS (20)	LDV/SOF versus LDV/SOF + RBV	12 weeks	74/77 (96)
					24 weeks	75/77 (97)
PegIFN/RBV	1	N	COSMOS (34)	SMV + SOF versus SMV + SOF + RBV	12 weeks	13/14 (93) versus 26/27 (96)
					24 weeks	14/15 (93) versus 19/24 (79)
Experienced or naive	1a	N	OPTIMIST-1 (35)	SMV + SOF	8 weeks	92/116 (79)
					12 weeks	112/116 (97)
Experienced or naive	1b	N	OPTIMIST-1 (35)	SMV + SOF	8 weeks	36/39 (92)
					12 weeks	38/39 (97)

Naive	1	N	AVIATOR (96)	OBV/PTV/r + DSV versus OBV/PTV/r + DSV + RBV	12 weeks	70/79 (89) [§] versus 76/79 (96) [§]
Naive	1a	N	PEARL-IV (30)	OBV/PTV/r + DSV versus OBV/PTV/r + DSV + RBV	12 weeks	185/205 (90) versus 97/100 (97)
Naive	1b	N	PEARL-III (28-30)	OBV/PTV/r + DSV versus OBV/PTV/r + DSV + RBV	12 weeks	209/209 (100) versus 209/210 (99.5)
PegIFN/RBV	1b	N	PEARL-II (28,29,31)	OBV/PTV/r + DSV versus OBV/PTV/r + DSV + RBV	12 weeks	91/91 (100) versus 86/88 (98)
Naive	1a	N	SAPPHIRE-I (26,28,29)	OBV/PTV/r + DSV + RBV	12 weeks	308/322 (96)
Naive	1b	N	SAPPHIRE-I (26)	OBV/PTV/r + DSV + RBV	12 weeks	148/151 (98)
PegIFN/RBV	1a	N	SAPPHIRE-II (27)	OBV/PTV/r + DSV + RBV	12 weeks	166/173 (96)
PegIFN/RBV	1b	N	SAPPHIRE-II (27)	OBV/PTV/r + DSV + RBV	12 weeks	119/123 (97)
PegIFN/RBV or naive	1a	Y (100)	TURQUOISE-II (28,29,32)	OBV/PTV/r + DSV + RBV	12 weeks	124/140 (89)
					24 weeks	115/121 (95)
PegIFN/RBV or naive	1b	Y (100)	TURQUOISE-II (32)	OBV/PTV/r + DSV + RBV	12 weeks	67/68 (99)
					24 weeks	51/51 (100)
PegIFN/RBV or naive	1b	Y(100)	TURQUOISE-III (33)	OBV/PTV/r + DSV	12 weeks	60/60 (100)
PegIFN/RBV + telaprevir or boceprevir or naive	1	N	Sulkowski et al., 2014 (70)	DCV + SOF versus DCV + SOF + RBV	12 weeks	41/41 (100) versus 39/41 (95)

					24 weeks	35/35 (100) versus 34/35 (97)
Experienced or naive	1–6	Y (30)	ALLY-1 (52)	DCV + SOF + RBV	12 weeks	100/113 (88)
PegIFN/RBV or naive	1a	Y (67) [‡]	C-WORTHY (59)	GZR + EBR versus GZR + EBR + RBV	12 + 18 weeks combined	76/82 (93) versus 76/81 (94)
PegIFN/RBV or naive	1b	Y (67) [‡]	C-WORTHY (59)	GZR + EBR versus GZR + EBR + RBV	12 + 18 weeks combined	40/41 (98) versus 46/46 (100)
PegIFN/RBV (non-responder)	1	Y*	Jacobson et al., 2015 (37)	GZR + EBR versus GZR + EBR + RBV	12 weeks	34/37 (92)
					16 + 18 weeks combined	33/33 (100)
PegIFN/RBV ± telaprevir or bocoprevir (prior on-treatment failure)	1a	Y (36) [‡]	Thompson et al., 2015 (38)	GZR + EBR versus GZR + EBR + RBV	12 weeks	62/69 (90) versus 75/80 (94)
					16 + 18 weeks combined	49/52 (94) versus 54/54 (100)
Naive	1b	N	Serfaty et al., 2015 (40)	GZR + EBR versus GZR + EBR + RBV	8 weeks	29/31 (94) versus 27/30 (90)
Experienced or naive	1a	Y (100)	C-SALT (45)	GZR + EBR	12 weeks	24/27 (89)
Experienced or naive	1b	Y (100)	C-SALT (45)	GZR + EBR	12 weeks	3/3 (100)

*Excludes decompensated cirrhosis; [†]Cirrhosis or bridging fibrosis; [‡]Proportion of cirrhotic patients across the whole study population (data are not provided for subgroups presented here); [§]Sustained virologic response at 24 weeks (SVR24); Patients with METAVIR score F0–F3 or Child-Pugh score A; [¶]Patients with Child-Pugh score B or C.

DCV, daclatasvir; DSV, dasabuvir; EBR, elbasvir; GT, genotype; GZR, grazoprevir; HCV, hepatitis C virus; IFN, interferon; LDV, ledipasvir; NR, not reported; OBV, ombitasvir; PegIFN, pegylated interferon; PI, protease inhibitor; PTV, paritaprevir; r, ritonavir; RBV, ribavirin; SMV, simeprevir; SOF, sofosbuvir; SVR, sustained virologic response.

Table 2: Comparative data evaluating the tolerability of ribavirin in GT1 HCV patients treated with interferon-containing and interferon-free regimens.


Study name	Population	Regimen	Safety		
			SAEs (%)	Discontinued treatment due to AE (%)	Hemoglobin level (<10 g/dL) (%)
McHutchinson et al., 1998 (1)	Naive, GT1–3, ± cirrhosis	24 or 48 wks IFN versus IFN + RBV	NR	9 (24 wks) 14 (48 wks) versus 8 (24 wks) 21 (48 wks)	0 (24 wks) 0 (48 wks) versus 7 (24 wks) 9 (48 wks)
Poynard et al., 1998 (80)	Naive, GT1–6, ± cirrhosis	24 or 48 wks IFN versus IFN + RBV	NR	NR (24 wks) 13 (48 wks) versus 8 (24 wks) 19 (48 wks)	NR
Fried et al., 2002 (2)	Naive, GT1–4, ± cirrhosis	PegIFN versus PegIFN + RBV	NR	6 versus 7	[Hemoglobin <12g/dL in women; <13g/dL in men] 4 versus 23
ION-1 (15)	Naive, GT1, ± cirrhosis	12 or 24 wks LDV/SOF versus LDV/SOF + RBV	<1 (12 wks) 8 (24 wks) versus 3 (12 wks) 3 (24 wks)	0 (12 wks) 2 (24 wks) versus 0 (12 wks) 3 (24 wks)	0 (12 wks) 0 (24 wks) versus 9 (12 wks) 7 (24 wks)
ION-2 (16)	PegIFN ± NS3/4A PI, GT1	12 or 24 wks LDV/SOF versus LDV/SOF + RBV	0 (12 wks) 6 (24 wks) versus 0 (12 wks)	0 versus 0	0 (12 wks) 2 (24 wks) versus 2 (12 wks)

			3 (24 wks)		8 (24 wks)
ION-3 (17)	Naive, GT1, no cirrhosis	8 or 12 wks LDV/SOF versus 8 wks LDV/SOF + RBV	2 (8 wks) 2 (12 wks) versus <1	0 (8 wks) 1 (12 wks) versus <1	0 (8 wks) <1 (12 wks) versus 5
PEARL-IV (30)	Naive, GT1a, no cirrhosis	OBV/PTV/r + DSV versus OBV/PTV/r + DSV + RBV	0.5 versus 3	1 versus 0	0 versus 4
PEARL-III (30)	Naive, GT1b, no cirrhosis	OBV/PTV/r + DSV versus OBV/PTV/r + DSV + RBV	2 versus 2	0 versus 0	0 versus 9
PEARL-II (31)	PegIFN/RBV, GT1b, no cirrhosis	OBV/PTV/r + DSV versus OBV/PTV/r + DSV + RBV	2 versus 2	0 versus 2	0 versus 1
SAPPHIRE-I (26)	Naive, GT1, no cirrhosis	Placebo versus OBV/PTV/r + DSV + RBV	0 versus 2	0.6 versus 0.6	0 versus 6
SAPPHIRE-II (27)	PegIFN/RBV, GT1, no cirrhosis	Placebo versus OBV/PTV/r + DSV + RBV	1 versus 2	0 versus 1	0 versus 5
TURQUOISE-II (32)	PegIFN/RBV or naive, GT1, with cirrhosis	OBV/PTV/r + DSV + RBV	6	2	9
ALLY-1 (52)	Experienced or naive, GT1-6, with cirrhosis	DCV + SOF + RBV	13	2	[hemoglobin <9 g/dL] 6


C-EDGE (60)	PegIFN/RBV, GT1, ± cirrhosis	12 or 16 wks GZR + EBR	4 (12 wks) 3 (16 wks)	1 (12 wks) 0 (16 wks)	0 (12 wks) 0 (16 wks)
		versus GZR + EBR + RBV	versus 3 (12 wks) 4 (16 wks)	versus 1 (12 wks) 5 (16 wks)	versus 9 (12 wks) 21 (16 wks)

DCV, daclatasvir; DSV, dasabuvir; EBR, elbasvir; GT, genotype; GZR, grazoprevir; HCV, hepatitis C virus; IFN, interferon; LDV, ledipasvir; NR, not reported; OBV, ombitasvir; PegIFN, pegylated interferon; PI, protease inhibitor; PTV, paritaprevir; r, ritonavir; RBV, ribavirin; SAE, serious adverse event; SOF, sofosbuvir; wks, weeks.


A



B



C



D

